Meeting
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
Authors
Rudolph M. Navari
Simon Williamson Clinic, Birmingham, AL
Rudolph M. Navari , Jennifer Le-Rademacher , Fabrice Smieliauskas , Kathryn Jean Ruddy , Thomas James Saphner , Heshan Liu , Beth Harlos , Adedayo A. Onitilo , Karthik Giridhar , Preet Paul Singh , Pavan S. Reddy , Flavio Kruter , George Raptis , Charles L. Loprinzi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT03578081
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 12107)
DOI
10.1200/JCO.2022.40.16_suppl.12107
Abstract #
12107
Poster Bd #
352
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.
First Author: Venkatraman Radhakrishnan
Poster
2021 ASCO Annual Meeting
Olanzapine or dexamethasone, with 5-HT3 receptor antagonist and NK-1 receptor antagonist, to prevent nausea and vomiting induced by cisplatin-based doublet chemotherapy: A non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial.
First Author: Zhigang Liu
Poster
2011 ASCO Annual Meeting
Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting.
First Author: P. J. Hesketh
Poster
2019 ASCO Annual Meeting
Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy (CT).
First Author: Lee S. Schwartzberg